These findings highlight CYR61 as a downstream effector of PI3K/AKT signaling in PCa and suggest its potential as a biomarker or therapeutic target, particularly in tumors responsive to IGF1 signaling. The gene discussed is IGF1; the disease is posterior cortical atrophy.